Navigation Links
EnVivo Initiates Phase IIb Alzheimer's Disease Trial For EVP-6124
Date:5/11/2010

.

Two previous studies with EVP-6124 in Alzheimer's disease patients demonstrated that it was well tolerated and produced significant effects on a variety of cognitive measures of brain function such as attention, memory and executive function (complex thinking tasks). EVP-6124 had procognitive effects in two separate clinical trials: one study conducted in Alzheimer's disease patients already treated with Acetyl Choline Esterase Inhibitors (AChEI) and one in Alzheimer's disease patients not on AChEI therapy (naive patients).

EVP-6124 is a selective agonist for the alpha-7 subtype of the nicotinic acetylcholine receptor and is being developed by EnVivo for potential cognitive enhancement in both schizophrenia and Alzheimer's patients. It has been shown to have excellent CNS penetration, oral bioavailability, pharmacokinetics and metabolic profile.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, cognitive disorders and schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase IIa clinical trials for cognition disorders in Alzheimer's disease and schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which has completed Phase I studies, and seve
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
2. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
3. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
4. EnVivo Pharmaceuticals Announces Executive Appointment
5. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
6. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
7. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union
10. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
11. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Research and Markets has ... Pulp & Paper Industry Report 2014" report to ... Pulp & Paper Industry Report 2014 is a professional ... global enzyme for pulp & paper industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... Beach County, Florida (PRWEB) August 27, 2014 ... Company Inc. (SCI) is announcing the creation of ... priority is to take the SCI’s philosophy of ... the company’s research and development actions are based ... , This new Scientific Advisory Board provides a ...
(Date:8/27/2014)... August 27, 2014 Remcom announces an ... with new features for the biomedical industry. The ... Biological Thermal Sensor, exclusive to the Bio-Pro version of ... of XFdtd, developed to calculate the biological effects of ... been added to all versions to expand engineers’ post-processing ...
(Date:8/26/2014)...  NeuroSigma, Inc., a Los Angeles ... today announced that it has filed a registration statement ... Commission relating to a proposed initial public offering of ... offered and the price range for the proposed offering ... will act as the book-running manager for the proposed ...
Breaking Biology Technology:Global Enzyme for Pulp & Paper Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3
... Inc. (NYSE: HGR ) announced net sales of $192.3 million ... million, or 7.6%, from $178.7 million in the prior year. ... per diluted share compared to $0.23 per diluted share for the ... sales increase for the quarter ended September 30, 2009 was primarily ...
... (OTC Bulletin Board: OXBO) today announced the expansion of the ... members. Appointed to the company,s board were Rene A. Eckert ... company board now has eight members. , Bill Chatfield most ... Service System from November of 2004 to May of this ...
... Ph.D., J.D., will be giving opening, introductory and concluding ... and IP Professionals. This exciting conference brings together ... service providers, and will be held Wednesday, November 4, ... Hotel at the University of Cincinnati. , Based ...
Cached Biology Technology:Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance 2Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance 3Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance 4Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance 5Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance 6Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance 7Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance 8Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance 9Oxygen Biotherapeutics, Inc. Expands Board of Directors 2
(Date:8/27/2014)... fish began exploring land and evolved into tetrapods today,s ... fish used their fishy bodies and fins in a terrestrial ... mysteries. , Researchers at McGill University published in the ... Polypterus , to help show what might have happened ... Polypterus is an African fish that can breathe ...
(Date:8/27/2014)... frequently found in forests has created a thriving habitat ... a new University of Georgia study has found. , ... in the early 1900s, is one of the most ... a dozen states in the past century, particularly in ... it can survive in widely diverse ecosystems and has ...
(Date:8/27/2014)... 2014 /PRNewswire-iReach/ -- The IEEE Engineering in Medicine and ... Annual International Conference (EMBC,14), this year being held at ... Chicago, Illinois , from Tuesday, August 26 through ... and industry professionals in science, medicine, and engineering are ... This year,s conference theme is ...
Breaking Biology News(10 mins):Walking fish reveal how our ancestors evolved onto land 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 3Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3
... microorganisms, living together with human cells, usually in harmony. ... only about one to two percent of the bodys ... illness. Yet, surprisingly little is known about the role ... play in human health and disease. To better understand ...
... VCU Life Sciences Survey is the first poll to ... skin cells can be used to create stem cells ... of this development, more than six in 10, or ... cell research is still needed, 22 percent say this ...
... Line Utilizes World,s Best Selling Silicon ... ... Dec. 18 ,AuthenTec, Inc. (Nasdaq: AUTH ), the world,s ... Bulletin Board: BMRX), a,leading provider of biometrically secured consumer products, ...
Cached Biology News:NIH launches Human Microbiome Project 2NIH launches Human Microbiome Project 3NIH launches Human Microbiome Project 4NIH launches Human Microbiome Project 5Widespread support for nonembryonic stem cell research, VCU Life Sciences Survey shows 2bioMETRX, Inc. Announces Integration of AuthenTec Fingerprint Sensor in smartTOUCH(TM) Product Line 2bioMETRX, Inc. Announces Integration of AuthenTec Fingerprint Sensor in smartTOUCH(TM) Product Line 3